MedPath

Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy

Phase 3
Completed
Conditions
Infection
Multiple Myeloma
Interventions
Registration Number
NCT00002850
Lead Sponsor
Gary Morrow
Brief Summary

RATIONALE: Giving antibiotics may be effective in preventing or controlling early infection in patients with multiple myeloma and may improve their response to chemotherapy.

PURPOSE: This randomized clinical trial is studying antibiotics to see how well they work compared to no antibiotics in preventing early infection in patients with multiple myeloma.

Detailed Description

OBJECTIVES:

* Evaluate whether oral antibiotic prophylaxis with co-trimoxazole (TMP-SMX) versus ciprofloxacin (CPFX) or ofloxacin versus no prophylaxis will significantly reduce rates of serious bacterial infections during the first 3 months of chemotherapy in patients with multiple myeloma.

* Determine whether antibiotic prophylaxis with TMP-SMX or CPFX (or ofloxacin) is associated with an increased incidence of nonbacterial infection or an increased rate of infection from organisms resistant to prophylactic antibiotics.

* Evaluate whether oral antibiotic prophylaxis with CPFX or ofloxacin is as effective as TMP-SMX without the associated toxic effects.

* Evaluate whether protection against early infection in multiple myeloma patients can improve their response to initial chemotherapy.

OUTLINE: This is a randomized, multicenter study. Patients are stratified by participating center. Patients are randomized to 1 of 2treatment arms.

* Arm I: Patients receive co-trimoxazole every 12 hours for 2 months followed by observation for 2 months.

* Arm II: Patients receive oral ciprofloxacin or ofloxacin every 12 hours for 2 months followed by observation for 1 month.

* Arm III: The patient will receive no prophylaxis.

Patients continue their randomly assigned treatment throughout any infection in addition to any treatment needed for infection. Patients also remain on their randomly assigned treatment if chemotherapy is discontinued, changed, or delayed during the 3 month study.

Patients are followed at 6 months, 1 year, and 2 years.

PROJECTED ACCRUAL: A total of 212 patients (71 per treatment arm) will be accrued for this study.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
212
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
TMP-SMX160 mg trimethoprim and 800 mg sulfamethoxazoleTMP-SMX: 160 mg trimethoprim and 800 mg sulfamethoxazole every 12 hours
Ciprofloxacin or ofloxacinciprofloxacinQuinolone: Ciprofloxacin 500 mg every 12 hours or Ofloxacin400 mg every 12 hours.
Ciprofloxacin or ofloxacinofloxacinQuinolone: Ciprofloxacin 500 mg every 12 hours or Ofloxacin400 mg every 12 hours.
Primary Outcome Measures
NameTimeMethod
Proportion of Patients Experiencing a Serious Bacterial InfectionFirst three months of chemotherapy

This study evaluated the impact of prophylactic antibiotics on the incidence of serious bacterial infections (SBIs) during the first 2 months of treatment in patients with newly diagnosed multiple myeloma. Patients with multiple myeloma receiving initial chemotherapy were randomized on a 1:1:1 basis to daily ciprofloxacin, trimethoprim-sulfamethoxazole, or observation and evaluated for SBI for the first 2 months of treatment.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (45)

CCOP - Columbus

🇺🇸

Columbus, Ohio, United States

St. Mary's Hospital Medical Center - Green Bay

🇺🇸

Green Bay, Wisconsin, United States

Siouxland Hematology-Oncology Associates, LLP

🇺🇸

Sioux City, Iowa, United States

St. Luke's Regional Medical Center

🇺🇸

Sioux City, Iowa, United States

CCOP - Kalamazoo

🇺🇸

Kalamazoo, Michigan, United States

CCOP - Kansas City

🇺🇸

Kansas City, Missouri, United States

Our Lady of Mercy Medical Center Comprehensive Cancer Center

🇺🇸

Bronx, New York, United States

Instituto Nacional de Enfermedades Neoplasicas

🇵🇪

Lima, Peru

CCOP - Dayton

🇺🇸

Dayton, Ohio, United States

Bay Area Cancer Care Center at Bay Area Medical Center

🇺🇸

Marinette, Wisconsin, United States

CCOP - Marshfield Clinic Research Foundation

🇺🇸

Marshfield, Wisconsin, United States

MetroHealth Cancer Care Center at MetroHealth Medical Center

🇺🇸

Cleveland, Ohio, United States

Lewistown Hospital

🇺🇸

Lewistown, Pennsylvania, United States

CCOP - Metro-Minnesota

🇺🇸

St. Louis Park, Minnesota, United States

Penn State Cancer Institute at Milton S. Hershey Medical Center

🇺🇸

Hershey, Pennsylvania, United States

CCOP - Hematology-Oncology Associates of Central New York

🇺🇸

East Syracuse, New York, United States

CCOP - Northwest

🇺🇸

Tacoma, Washington, United States

Green Bay Oncology, Limited - Sturgeon Bay

🇺🇸

Sturgeon Bay, Wisconsin, United States

Pretoria Academic Hospital

🇿🇦

Pretoria, South Africa

Avera Cancer Institute

🇺🇸

Sioux Falls, South Dakota, United States

Chester County Hospital

🇺🇸

West Chester, Pennsylvania, United States

Dickinson County Healthcare System

🇺🇸

Iron Mountain, Michigan, United States

Mayo Clinic Cancer Center

🇺🇸

Rochester, Minnesota, United States

Green Bay Oncology, Limited - Oconto Falls

🇺🇸

Oconto Falls, Wisconsin, United States

Green Bay Oncology, Limited at St. Mary's Hospital

🇺🇸

Green Bay, Wisconsin, United States

St. Vincent's Comprehensive Cancer Center - Manhattan

🇺🇸

New York, New York, United States

Mercy Cancer Center at Mercy Medical Center

🇺🇸

Canton, Ohio, United States

CCOP - Wichita

🇺🇸

Wichita, Kansas, United States

CCOP - Columbia River Oncology Program

🇺🇸

Portland, Oregon, United States

CCOP - Greenville

🇺🇸

Greenville, South Carolina, United States

Sanford Cancer Center at Sanford USD Medical Center

🇺🇸

Sioux Falls, South Dakota, United States

Cedar Rapids Oncology Associates

🇺🇸

Cedar Rapids, Iowa, United States

MBCCOP - Gulf Coast

🇺🇸

Mobile, Alabama, United States

Mobile Infirmary Medical Center

🇺🇸

Mobile, Alabama, United States

McCreery Cancer Center at Ottumwa Regional

🇺🇸

Ottumwa, Iowa, United States

Mercy Medical Center - Sioux City

🇺🇸

Sioux City, Iowa, United States

Beth Israel Deaconess Medical Center

🇺🇸

Boston, Massachusetts, United States

Green Bay Oncology, Limited - Escanaba

🇺🇸

Escanaba, Michigan, United States

Hunterdon Regional Cancer Center at Hunterdon Medical Center

🇺🇸

Flemington, New Jersey, United States

Warren Hospital

🇺🇸

Phillipsburg, New Jersey, United States

CCOP - Southeast Cancer Control Consortium

🇺🇸

Goldsboro, North Carolina, United States

Mount Nittany Medical Center

🇺🇸

State College, Pennsylvania, United States

Green Bay Oncology, Limited at St. Vincent Hospital Regional Cancer Center

🇺🇸

Green Bay, Wisconsin, United States

St. Vincent Hospital Regional Cancer Center

🇺🇸

Green Bay, Wisconsin, United States

Medical X-Ray Center, PC

🇺🇸

Sioux Falls, South Dakota, United States

© Copyright 2025. All Rights Reserved by MedPath